参松养心胶囊联合维拉帕米治疗室性心动过速的疗效观察
|
摘要
目的研究参松养心胶囊联合盐酸维拉帕米缓释片治疗室性心动过速的临床疗效。方法选取2016年8月—2017年7月荆州市第二人民医院接收的120例室性心动过速患者作为研究对象,将所有患者随机分为对照组和治疗组,每组各60例。对照组患者清晨口服盐酸维拉帕米缓释片,1片/次,1次/d。治疗组在对照组的基础上口服参松养心胶囊,3粒/次,3次/d。两组均持续治疗4周。观察两组患者的临床疗效,比较两组治疗前后的心率、PR间期、QT间期、复律时间和左心室功能。结果治疗后,对照组和治疗组的总有效率分别为88.33%、93.33%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组心率、QT间期、PR间期和复律时间均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组各指标均显著低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组左心室射血分数(LVEF)明显升高,左心室收缩末期内径(LVESD)和左心室舒张末期内径(LVEDD)均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组左心室功能明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论参松养心胶囊联合盐酸维拉帕米缓释片治疗室性心动过速具有较好的疗效,能够显著改善患者心率和心功能,安全性较好,值得临床推广应用。
Objective To study the clinical efficacy of Shensong Yangxin Capsules combined with Verapamil Hydrochloride Sustained-release Tablets in treatment of ventricular tachycardia. Methods Patients(120 cases) with ventricular tachycardia in The Second Hospital of Jingzhou from August 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Verapamil Hydrochloride Sustained-release Tablets in the morning, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the heart rate, QT interval, PR interval, cardioversion time, and left ventricular function in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were88.33% and 93.33%, respectively, and there was difference between two groups(P < 0.05). After treatment, the heart rate, QT interval,PR interval, and cardioversion time in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And these indicators levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, LVEF was significantly increased, but LVESD and LVEDD were significantly decreased, and there were differences in the same group(P < 0.05). And the left ventricular function indexes in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Shensong Yangxin Capsules combined with Verapamil Hydrochloride Sustained-release Tablets has good clinical effect in treatment of ventricular tachycardia, can significantly improve heart rate and cardiac function with high safety, which has a certain clinical application value.
Objective To study the clinical efficacy of Shensong Yangxin Capsules combined with Verapamil Hydrochloride Sustained-release Tablets in treatment of ventricular tachycardia. Methods Patients(120 cases) with ventricular tachycardia in The Second Hospital of Jingzhou from August 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Verapamil Hydrochloride Sustained-release Tablets in the morning, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shensong Yangxin Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the heart rate, QT interval, PR interval, cardioversion time, and left ventricular function in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were88.33% and 93.33%, respectively, and there was difference between two groups(P < 0.05). After treatment, the heart rate, QT interval,PR interval, and cardioversion time in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And these indicators levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, LVEF was significantly increased, but LVESD and LVEDD were significantly decreased, and there were differences in the same group(P < 0.05). And the left ventricular function indexes in the treatment group after treatment were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Shensong Yangxin Capsules combined with Verapamil Hydrochloride Sustained-release Tablets has good clinical effect in treatment of ventricular tachycardia, can significantly improve heart rate and cardiac function with high safety, which has a certain clinical application value.
引文
[1]黄震华.非持续性室性心动过速的治疗进展[J].中国新药与临床杂志,2015,34(1):23-27.
[2]李成浩,路兰.维拉帕米治疗特殊类型室性心动过速的临床价值[J].心肺血管病杂志,2007,26(4):233,235.
[3]吴优.参松养心胶囊对儿茶酚胺敏感性室性心动过速作用的探讨[J].大众科技,2016,18(1):55-58.
[4]朱文玲.内科疾病诊断与疗效标准[M].上海:上海中医药大学出版社,2006:21-23.
[5]王群山,李毅刚.室性心动过速的治疗进展[J].国际心血管病杂志,2007,34(4):227-232.
[6]姚焰.致心律失常性右心室心肌病室性心动过速的治疗进展[J].心血管病学进展,2008,29(6):823-825.
[7]邹利奋.参松养心胶囊联合胺碘酮治疗老年室性心律失常疗效观察[J].上海中医药杂志,2012,46(5):55.
[8]许宗凡,谢后光,杜小玉.维拉帕米治疗阵发性室上性心动过速18例临床分析[J].广西医学,2010,32(4):505-506.
[2]李成浩,路兰.维拉帕米治疗特殊类型室性心动过速的临床价值[J].心肺血管病杂志,2007,26(4):233,235.
[3]吴优.参松养心胶囊对儿茶酚胺敏感性室性心动过速作用的探讨[J].大众科技,2016,18(1):55-58.
[4]朱文玲.内科疾病诊断与疗效标准[M].上海:上海中医药大学出版社,2006:21-23.
[5]王群山,李毅刚.室性心动过速的治疗进展[J].国际心血管病杂志,2007,34(4):227-232.
[6]姚焰.致心律失常性右心室心肌病室性心动过速的治疗进展[J].心血管病学进展,2008,29(6):823-825.
[7]邹利奋.参松养心胶囊联合胺碘酮治疗老年室性心律失常疗效观察[J].上海中医药杂志,2012,46(5):55.
[8]许宗凡,谢后光,杜小玉.维拉帕米治疗阵发性室上性心动过速18例临床分析[J].广西医学,2010,32(4):505-506.